MK-677 12.5mg

Name: MK-677 12.5mg
SKU: PL-12.5MG-PI01
Price: 150.00 USD
Availability: InStock

Brands PeptideLion

$150.00

out of stock

Sku:

PL-12.5MG-PI01

Brands: PeptideLion

Description

Overview

What Is Mk-677 (Ibutamoren)?

MK 677 for sale (also known as ibutamoren) promotes the secretion of the growth hormone (GH) and increases insulin-like growth factor 1 (IGF-1). Ibutamoren increases growth hormone levels by mimicking the action of the hormone ghrelin and binding to one of the ghrelin receptors (GHSR) in the brain. Activated GHSR stimulates growth hormone release from the brain. Clinical studies describe only the effects ibutamoren has on appetite and as expected, like ghrelin, ibutamoren increases it. GHSR is found in brain regions that control appetite, pleasure, mood, biological rhythms, memory, and cognition. Therefore, we can expect that ibutamoren may also affect these functions. It increases growth hormone levels with little or no increase in other hormones, such as cortisol. Cortisol suppresses the immune system, reduces wound healing, and impairs learning and memory, and it’s usually not good to have this hormone elevated.

Scientific Information

The reversal of diet-induced negative nitrogen balance by GH suggests a possible therapeutic role for GH treatment in catabolic patients. A double-blind, randomized, placebo-controlled, two-period cross-over study was designed to investigate whether MK-677, an orally active nonpeptide mimic of GH-releasing peptide, can reverse diet-induced protein catabolism. Eight healthy volunteers (ages 24-39 yr) were calorically restricted (18 kcal/kg.day) for two 14-day periods. During the last 7 days of each diet period, subjects received either oral MK-677 25 mg or placebo once daily. There was a 14- to 21-day washout interval between periods. During the first week of caloric restriction (i.e. diet alone), daily nitrogen losses were similar for both treatment groups (mean +/- SE; MK-677 group -2.67 +/- 0.40 g/day vs. placebo group -2.83 +/- 0.26 g/day).

During the second week (diet and study drug), the mean daily nitrogen balance was 0.31 +/- 0.21 g/day in the MK-677 treatment group compared with -1.48 +/- 0.21 g/day in the placebo group (P < 0.01). MK-677 improved nitrogen balance integrated over the 7 days of treatment; the area under the curve day 8-14 nitrogen balance response was +2.69 +/- 5.0 (SE) for MK-677 and -8.97 +/- 5.26 g.day for placebo (P < 0.001). MK-677 produced a peak GH response of 55.9 +/- 31.7 micrograms/L after a single dose (day 1 of treatment) and 22.6 +/- 9.3 micrograms/L after a week of dosing compared with placebo treatment peak GH values of approximately 9 (treatment day 1) and approximately 7 micrograms/L (treatment day 7).

Following the initial 7-day caloric restriction, insulin-like growth factor-I (IGF-I) declined from 232 +/- 25 to 186 +/- 19 ng/mL in the MK-677 group and from 236 +/- 19 to 174 +/- 23 ng/mL in the placebo group. Mean IGF-I concentration increased significantly during MK-677 to 264 +/- 31 ng/mL (mean for the last 5 days of treatment) compared with 188 +/- 19 ng/mL with placebo (P < 0.01).

No significant difference in IGF binding protein-2 was found between the MK-677 and placebo treatments. However, the mean in IGF binding protein-3 for the last 5 days of MK-677 treatment was also significantly increased to 3273 +/- 330 ng/mL (mean +/- SE) compared with placebo 2604 +/- 253 ng/mL (P < 0.01). Neither the serum cortisol nor the PRL response was significantly greater after 7 days of MK-677 dosing compared with 7 days of placebo. MK-677 (25 mg) was generally well tolerated and without clinically significant adverse experiences. In conclusion, MK-677 reverses diet-induced nitrogen wasting, suggesting that if these short-term anabolic effects are maintained in patients who are catabolic because of certain acute or chronic disease states, it may be useful in treating catabolic conditions.

Research Highlights

MK-677 has been shown to provide numerous health benefits for individuals with certain conditions. Those with low bone density, those who have trouble sleeping at night, and individuals with catabolic conditions can all benefit greatly from the use of MK-677. The ability of the MK-677 secretagogue to effectively secrete Growth Hormone and IGF-1 proves to be a useful tool for many different populations. MK-677 has been shown through numerous studies to benefit the elderly, those with obesity, have problems sleeping, have low bone density, and others. For these populations, MK-677 can be used as a helpful tool to combat issues that can be caused in large part due to a lack of Growth Hormone and IGF-1.

Ibutamoren should not be used while pregnant or breastfeeding. Always tell your physician about all medications and supplements, especially corticosteroids and thyroid medications, that you are taking. Common side effects of Ibutamoren include increased hunger, slight muscle pain, and flushing of the face; and less than 1 percent of patients report dizziness, headache, or hyperactivity.